Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cyberonics VNS Therapy

This article was originally published in The Gray Sheet

Executive Summary

Panel-track, 87-volume PMA supplement for use of the vagus nerve stimulation system for adjunctive, drug treatment-resistant depression is submitted to FDA. The firm plans to present pivotal D-02 trial data in May 2004 at the American Psychiatric Association meeting and gain approval by October 2004 with expedited review (1"The Gray Sheet" July 28, 2003, p. 18). Separately, Cyberonics announces Nov. 5 a 12% jump in sales to $29.3 mil., and near tripling of earnings to $3.8 mil. in the fiscal second quarter (ended Oct. 24)...

You may also be interested in...



Cyberonics Expects VNS Will Capture 4% Of U.S. Depression Market By 2010

Cyberonics anticipates FDA approval of a depression indication for its VNS Therapy vagus nerve stimulation system by October 2004

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel